Treatment of venous thromboembolism;Tratamiento de la enfermedad tromboembolica venosa

Medicina Clinica

Volumn 115, Issue 6, 2000, Pages 224-235

  Rocha, E ^a   Panizo, C ^a   Lecumberri, R ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; CERTOPARIN; CY 222; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; REVIPARIN; STREPTOKINASE; TINZAPARIN; UROKINASE; HEPARIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; EMBOLECTOMY; HUMAN; META ANALYSIS; MORTALITY; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; VENA CAVA FILTER; ADULT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; FIBRINOLYTIC THERAPY; MALE; ORAL DRUG ADMINISTRATION; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZED CONTROLLED TRIAL; RISK; THROMBECTOMY; TIME; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; META-ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RANDOMIZED CONTROLLED TRIALS; RISK; THROMBECTOMY; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; TIME FACTORS; VENA CAVA FILTERS; VENOUS THROMBOSIS; WARFARIN;

EID: 0034622189     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71516-8     Document Type: Review

References (148)

1. Initial treatment of venous thromboembolism
2. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
3. The long-term clinical course of acute deep venous thrombosis
4. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled clinical trial
5. Heparin therapy in thrombolic disease
6. Mortality in patients treated for pulmonary embolisml
7. Heparin in the treatment of pulmonary thromboembolism
8. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis
9. Management of heparin therapy: Controlled prospective trial
10. Randomized prospective trial of continuous versus intermittent heparin therapy
11. Heparin therapy: A randomized prospective study
12. Antihrombotic therapy for venous thromboembolic disease
13. Treatment of venous thromboembolism
14. A standard heparin nomogram for the management of heparin therapy
15. Optimal therapeutic level of heparin therapy in patients with venous thrombosis
16. The weight-based heparin dosing nomogram compared with a 'standard care nomogram'
17. Heparin binding to plasma proteins, an important mechanism for heparin resistance
18. Comparison of the nonspecific binding of unfractionated heparin and low molecular weight heparin to plasma proteins
19. Guide to anticoagulant therapy. Part 1: Heparin
20. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time
21. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thormbosis
22. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
23. Establishing a therapeutic range for heparin therapy
24. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis
25. An objective study of alternative methods of heparin administration
26. Subcutaneous administration of heparin: Randomised comparison with intravenous administration of heparin to patients with deep vein thombosis
27. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thombosis: Randomized trial
28. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multi-centre prospective randomized trial
29. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis - A randomized clinical trial
30. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein trombosis
31. Heparin-induced thrombocytopenia
32. Heparin-induced thrombocytopenia: A prospective study
33. Heparin-induced thrombocytopenia: A comparison of three heparin preparations
34. Heparin-induced thrombocytopenia
35. Safety and efficacy of warfarin after early after submassive venous thrombosis or pulmonary embolism
36. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
37. Heparinas de bajo peso molecular
38. Low-molecular-weight heparins
39. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
40. Anticoagulant and antithrombotic effects of heparin and los molecular weight heparin fragments in rabbits
41. A new low molecular weight heparin derivative, in vitro and in vivo studies
42. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation
43. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thombosis
44. Subcutaneous heparin treatment of deep venous thrombosis a comparison of unfractionated and low molecular weight heparin
45. A new treatment of deep venous thrombosis: Low molecuilar weight heparin fractions. Randomized study
46. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects
47. Deep vein thrombosis of the legs: New therapy by means of low molecular weight heparins
48. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
49. Etude Multicentrique Francaise. Traitement des thromboses veineuses profondes constituees. Etude comparative d'un fragment d'heparine de bas poids moleculaire (Fragmine) administree par voie sous-cutanee et de l'heparine standard administree par voie intravenineuse continue
50. Two daily subcutaneous injections of fragmin as compared with in travenous standard heparin in the treatment of deep venous thrombosis (DVT)
51. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients
52. A Collaborative European Multicentre Study: A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
53. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
54. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
55. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
56. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractioned heparin in the treatment of proximal deep vein thrombosis
57. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis
58. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
59. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
60. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
61. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
62. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
63. Low-molecular-weight hepain in the treatment of patients with venous thromboembolism
64. Low molecular weight heparin: A critical analysis of clinical trials
65. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
66. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
67. Low-molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolsim
68. The treatment of deep vein thrombosis and pulmonary embolism
69. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acture deep venous thrombosis. A metaanalysys of randomized, controlled trials
70. Does the low molecular weight heparins improve the efficacy and safety in the treatments of deep venous thrombosis? A meta-analysis
71. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an out patient setting Swedish Venous Thrombosis Dalteparin Trial Group
72. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin
73. Expanding eligibility for out patient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin
74. Assessment of outpatient treatment of deep vein thrombosis with low-molecular-weight heparin
75. Dalteparin for deep venous thrombosis: A hospital-in-the-home program
76. Tratamiento domiciliario de las trombosis venosas profundas con heparina de bajo peso molecular
77. Dalteparin for deep venous thrombosis a hospital-in-the-home program
78. Outpatient treatment of deep vein thrombosis translating clinical trials into practice
79. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the durative treatment of submassive pulmonary embolism. A dose-ranging study
80. Randomized comparison of LMWH versus standard heparin in the initial treatment of pulmonary embolism
81. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
82. A comparisor of low-molecular-weight hepain with unfractionated heparin for acute pulmonary embolism
83. Treament of proximal vein thrombosis with subcutaneous low-molecular weight heparin vs intravenous heparin: An economic perspective
84. Replacing in patient care by out-patient care in the treatment of deep venous thrombosis - An economic evaluation
85. Low-molecular-weight heparins compared with unfracnionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
86. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11) - A three way cross-over study in healthy volunteers
87. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - A dose-finding study within the therapeutical range
88. Relacion estructura quimica-actividad de las heparinas de bajo peso molecular (HBPM) Hacia una segunda generacion de heparinas de bajo peso molecular?
89. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery
90. A comparative, double-blind, randomized trial of a new second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty
91. A multicentre randomized trial of the effect of low-molecular-weight heparin (Rovi 11) and unfractionated heparin in the acute and long-term treatment of deep vein thrombosis (comunicacion personal)
92. Streptokinase therapy for deep-vein thrombosis: A comprehensive review of the English literature
93. Thrombolytic therapy for the treatment of acute pulmonary embolism
94. Thrombolytic therapy for deep vein thrombosis
95. Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep vein thrombosis
96. A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis
97. Catheter-directed lysis of ileofemoral vein thrombosis with use of rt-PA
98. The Urokinase Pulmonary Embolism Trial. A national cooperative study
99. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism
100. A controlled trial of streptokinase and heparin in the treatment of major pulmonary embolism
101. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism
102. Effect of thrombolytic therapy on pulmonary capillary blood volume in patients with pulmonary embolism
103. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease
104. Streptokinase and heparin alone in massive pulmonary embolism: A randomized controlled trial
105. Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right-ventricular function and pulmonary perfusion
106. Controversies of different regimens of thrombolytic therapy in acute pulmonary embolism
107. Treatment of acute massive pulmonary embolism
108. Greenfield vena cava filter: Rationale and indications
109. Ingerior vena cava filters. Indications, safety, efectiveness
110. Twelve year clinical experience with the Greenfield vena cava filter
111. Vena cava filters for the prevention of pulmonary embolism
112. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
113. Free-floating thrombus and embolic risk in patients with angiographically confirmed proximal deep venous thrombosis. A prospective study
114. Long-term results of venous thrombectomy combined with temporary arteriovenous fistula
115. Five-year follow-up study of iliofemoral venous thrombectomy
116. Pulmonary embolectomy: A 25 year experience
117. Pulmonary embolectomy for acute massive pulmonary embolism: An analysis of 71 cases
118. Pulmonary embolectomy: A 20-year experience at one centre
119. Treatment of venous thromboembolism
120. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolism
121. Catheter embolectomy
122. Current status of percutaneous mechanical thrombectomy; Part I. General principles
123. Current status of percutaneous mechanical thrombectomy; Part III. Present and future applications
124. Current status of percutaneous mechanical thrombectomy; Part III. Present and future applications
125. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter
126. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
127. Warfarin sodium versus low-dose heparin in long-term treatment of venous thrombosis
128. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
129. A randomized trial comparing 5 mg and 10 mg warfarin loading doses
130. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
131. Different intensities of oral anticoagulant therapy in the treatment of proximal vein thrombosis
132. The management of thrombosis in the antiphospholipids antibody syndrome
133. Antiphospholipid antibodies and venous thromboembolism
134. Adjusted subcutaneous heparin versus warfarin sodium in the long-term tratment of venous thormbosis
135. Low-molecular-weignt heparin versus warfarin in the prevention of recurrences after ceep vein thrombosis
136. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
137. Placental transport of heparin
138. Safett of low-molecular-weight heparin in pregnancy: A systematic review
139. Maternal and fetal sequelae of anticoagulation during pregnancy
140. Use of antithrombotic agents during pregnancy
141. Recurrence of venous thromboembolism
142. Optimal duration of anticoagulation for deep vein thrombosis and pulmonary embolism
143. Deep vein thrombosis and the incidence of subsequent symptomatic cancer
144. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
145. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
146. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The Warfarin Optimal Duration Italian Trial (WODIT)
147. The duration of oral anticoagulant therapy aftra second episode of venous thromboembolism
148. Long-term treatment of venous thromboembolic disease